Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-world Experience With Combination Chemotherapy and Osimertinib in Poor Prognostic Group of Metastatic EGFR-mutated Lung Adenocarcinoma

NCT06918782 is registered in ClinicalTrials.gov with The University of Hong Kong as lead sponsor.

NCT NCT06918782
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06918782 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-world Experience With Combination Chemotherapy and Osimertinib in Poor Prognostic Group of Metastatic EGFR-mutated Lung Adenocarcinoma
Lead sponsor
The University of Hong Kong
Phase
Phase 2
Overall status
Not yet recruiting
Start date
May 1, 2025
Completion date
December 31, 2027
Enrollment
47 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer (nsclc)